GenomeDx said today that it has signed an agreement to test its Decipher GRID database of cancer genomic profiles with samples from prostate cancer clinical trials run by Janssen Pharmaceuticals. Under the terms of the deal, GenomeDx will test the samples in order to evaluate the association of prognostic and predictive genomic signatures from the Decipher GRID platform — which includes more...
While a relatively small number of clinical laboratories have achieved ISO 15189 accreditation, industry experts predict this number will continue to increase as healthcare executives understand not only the competitive advantage the accreditation confers but also the potential cost savings that labs can achieve through quality improvement.
A New Way to Subscribe – Contact Medi-Cal Subscription Service Representatives 2018 Update to PE4PW Income Eligibility Guidelines Reimbursement Rates Established for Select Mammography CPT-4 Codes Expanded TAR Clinical Criteria for DNA Sequence Analysis Procedures Updated TAR Criteria for Familial Hyperinsulinism Gene Analysis Automated Hemogram and RSV Laboratory Tests Added as CLIA-...
Updates to Publication 100-04, Chapters 1 and 27, to Replace Remittance Advice Remark (RARC) MA61 with N382
Change Request (CR) 10619 initiates both Medicare manual changes and operational changes related to the New Medicare Card. Medicare will replace the use of Remittance Advice Remark Code (RARC) MA61, referenced in the Medicare Claims Processing Manual, Chapters 1 and 27, with RARC N382 - missing/incomplete/invalid patient identifier (HICN or MBI). Effective for claims processed on or after the...
The US Preventive Services Task Force said today that men aged 55 to 59 should decide with their clinicians whether to pursue prostate specific antigen-based cancer screening. The update and its recommendations are supported by an evidence report and systematic review, and it aligns the USPSTF with American Cancer Society and the American Urological Association.
Agendia announced today that its MammaPrint 70-gene signature breast cancer recurrence risk test has received positive coverage decisions from Aetna, Cigna, and UnitedHealthcare. According to Agendia, the three insurers cover more than 85 million people in the US and internationally.
In order to manage the projected shortfall between the authorized budget for the current fiscal year, which ends June 30, 2018, and actual claims received from enrolled providers, the department is modifying its payment schedule effective immediately.
Claims received on or after July 1, 2018 with dates of service on or after February 26, 2018 will require a Z-code on the claim line if the service is covered under the MolDX Molecular Diagnostic Testing (MDT) LCD L35025.
- 1 of 411
- next ›